Multi-residue enantioselective analysis of chiral drugs in freshwater sediments.

EAGLESHAM, A., SCOTT, A. and PETRIE, B.

2020
Multi-residue enantioselective analysis of chiral drugs in freshwater sediments

Abbey Eaglesham1 · Arron Scott1 · Bruce Petrie1

Received: 27 May 2020 / Accepted: 17 June 2020 © The Author(s) 2020

Abstract
Pharmaceutical and illicit drugs are emerging contaminants found in the environment globally. Many are chiral and stereoisomerism plays an important role on their environmental fate and effects. However, investigations at the enantiomeric level are limited, particularly for complex particulate matrices such as sediments. This is due to further sample processing requirements and a lack of suitable analytical methods. Therefore, here a new enantioselective methodology is proposed for 15 drugs in sediment. Sample treatment by accelerated solvent extraction and solid phase extraction was critical for subsequent enantioselective separations. Using liquid chromatography–tandem mass spectrometry, a Chiral-V enantioselective column enabled multi-residue separations of anti-depressants, beta-blockers, beta-agonist, anti-histamine and stimulants. Method trueness for all enantiomers was 86–121% and method quantitation limits were below 3 ng g⁻¹ dry weight. Application of the method revealed the enantiomeric composition of fluoxetine, amphetamine, propranolol, venlafaxine and citalopram in sediment for the first time. All drugs except venlafaxine were present in non-racemic form, i.e. unequal enantiomer concentrations. This is significant considering drug toxicity towards benthic organisms could be enantiospecific.

Keywords
Vancomycin · Metabolite · Septic tank · Sewage · Wastewater · River

Introduction
Pharmaceutical and illicit drugs are emerging contaminants as their fate and effects in the environment are not fully understood (Cizmas et al. 2015; Wilkinson et al. 2017). The main source of drugs in the environment is the discharge of effluent from centralised wastewater treatment plants. However, septic tanks can play a significant role with 20% of United States households served by a septic tank or similar system (Schaider et al. 2017). In Scotland, 7% of the population is estimated to use a septic tank (Ramage et al. 2019). Nevertheless, little attention has been given to the impact of septic tanks to surrounding aquatic systems with respect to drugs.

Drug stereochemistry plays an essential role in the environmental behaviour of a drug. Approximately, 50% of drugs are chiral and exist as two or more enantiomers (Kasprzyk-Hordern 2010). Most drugs are dispensed in racemic form, i.e. equal concentration of all enantiomers, despite most of the pharmacological activity normally residing with one enantiomer. However, chiral drugs can be subject to enantiospecific metabolism in the human body and during wastewater treatment (Ribeiro et al. 2012). Therefore in the environment it is common to find chiral drugs enriched with one enantiomer. This is significant as enantiospecific toxicity can occur in the environment (Stanley et al. 2007). For example, S(+)-fluoxetine is ~ 10 times more toxic towards the protozoa Tetrahymena thermophila than R(−)-fluoxetine (De Andrés et al. 2009). Despite this knowledge there is still a lack of studies undertaken in the environment at the enantiomeric level, particularly for particulate matrices such as sediments. A contributing factor is the lack of good analytical methodologies available for these complex matrices.

Multi-residue enantioselective methods exist for biosolids applied to farmland as fertiliser (Evans et al. 2015) and soils (Petrie et al. 2018). However, no such methods exist for river sediments. Previously developed methods for sediments are
limited to a single therapeutic drug group. For example, methods exist for the anti-inflammatories ibuprofen, ketoprofen and flurbiprofen (Yuan et al. 2018), the antibiotic flumequine and its metabolite 7-hydroxyflumequine (Xue et al. 2018) and the antifungals econazole, ketoconazole and miconazole (Huang et al. 2013). However, numerous other chiral drugs have been reported in sediments, (Vazquez-Roig et al. 2010; Silva et al. 2011; Bagnis et al. 2018) with no information on their enantiomeric composition. Therefore, the objectives of the study were (i) to establish a new methodology for multi-residue enantioselective profiling of chiral drugs in sediments, and (ii) to determine the enantiomeric composition of chiral drugs present in sediments impacted by wastewater treatment plants and septic tanks.

**Experimental**

**Materials**

Analytical reference and deuterated surrogate standards were purchased from Sigma Aldrich (Gillingham, UK) and Toronto Research Chemicals (North York, Canada). The standards were R/S(±)-amphetamine, R/S(±)-methamphetamine, R/S(±)-atenolol, R/S(±)-chlorpheniramine, R/S(±)-citalopram, R/S(±)-desmethylcitalopram, R/S(±)-fluoxetine, R/S(±)-propranolol, R/S(±)-salbutamol, R/S(±)-venlafaxine, R/S(±)-desmethylvenlafaxine, R/S(±)-bisoprolol, R/S(±)-acebutolol, R/S(±)-metoprolol and R/S(±)-sotalol (Table S1). The deuterated surrogates were R/S(±)-amphetamine-d11, R/S(±)-methamphetamine-d11, R/S(±)-atenolol-d7, R/S(±)-chlorpheniramine-d8, R/S(±)-citalopram-d9, R/S(±)-fluoxetine-d9, R/S(±)-propranolol-d4, R/S(±)-salbutamol-d3, R/S(±)-venlafaxine-d6, R/S(±)-bisoprolol-d5, R/S(±)-acebutolol-d5, R/S(±)-metoprolol-d4, and R/S(±)-sotalol-d5. Mixed calibration standards were prepared in methanol at 0.01–250 ng mL−1 (including 200 ng mL−1 of each deuterated surrogate). These were stored at −20 °C and prepared weekly. HPLC grade methanol, acetic acid and ammonium acetate were purchased from Fisher Scientific (Loughborough, UK). Ultrapure water was 18.2 MΩ cm−1 quality. Sediment (~ 500 g) from the top 5 cm surface layer was collected for method development from the River Don, Aberdeenshire. This was frozen at −20 °C until further processing.

**Sample extraction**

Sediments were freeze dried and sieved (2 mm). Two grams of samples was spiked with a methanolic mixture of all deuterated surrogates at 50 ng g−1 and left for 1 h. Samples were mixed with 1 g diatomaceous earth and packed into 10 mL accelerated solvent extraction cells (Fisher Scientific). The remaining cell volume was filled with Ottawa sand and two 2–4 µm Dionex glass fibre filters (Fisher Scientific) fitted at each end. Sample extraction was performed using a Dionex ASE 350 (California, USA) system. The final method utilised an extraction solvent of 50:50 water:methanol at 100 °C. Two extraction cycles were undertaken per cell with the following settings: 5 min pre-heat, 5 min heat, 5 min static extraction time, 60% solvent flush volume, 150 s nitrogen purge and 1500 psi pressure. During development the influence of sample mass, extraction temperature and solvent composition to enantiomer recovery were investigated. Collected extracts (~22 mL) were diluted to 250 mL using water (<10% methanol content). Samples were loaded (5 mL min−1) onto Oasis HLB solid phase extraction cartridges (3 mL, 60 mg, Waters, Manchester, UK) preconditioned with 2 mL methanol and 2 mL water at 1 mL min−1. Enantiomer elution was in 4 mL methanol at 1 mL min−1. Extracts were dried at 40 °C under nitrogen and reconstituted in 0.5 mL mobile phase.

**Enantioselective liquid chromatography–tandem mass spectrometry**

Chromatographic analysis was undertaken using an Agilent 1200 series liquid chromatography system (Cheshire, UK) using an InfinityLab Poroshell 120 Chiral-V column (150 × 2.1 mm; 2.7 µm particle size) fitted with a 0.2 µm pre-filter. A polar ionic mobile phase consisting of 2 mM ammonium acetate in methanol containing 0.01% acetic acid at a flow rate of 0.15 mL min−1 was used (McKenzie et al. 2020). The column temperature was 15 °C whilst the injection volume was 10 µL. The detector was an Agilent 6420 triple quadrupole in positive electrospray ionisation mode. The capillary voltage was 4,000 V with a desolvation temperature of 350 °C and nitrogen gas flow of 12 L min−1. The nebulising pressure was 50 psi. Nebulising, desolvation and collision gases were nitrogen. Multiple reaction monitoring transitions and instrument performance data are compiled in Table S2 and Table S3.

**Study site**

A sub-catchment of the River Don, Aberdeenshire known to be impacted by septic tank discharge and not any centralised wastewater treatment plants was focused upon (Ramage et al. 2019). Five sampling locations were selected and ~100 g of sediment from the top 5 cm surface layer was collected. Samples were transported to the laboratory on ice and frozen at −20 °C in aluminium foil until further processing (as described in Sect. 2.2). Sediment was also collected from the River Don itself, approximately 7 km downstream of the nearest centralised wastewater treatment plant. Samples
were collected during October 2019 and all analysis was in triplicate.

**Results and discussion**

**Method development**

Vancomycin chiral selectors are popular due to their multi-residue separation capabilities (Ribeiro et al. 2013; Evans et al. 2015; Petrie et al. 2018). A Poroshell 120 Chiral-V column was used due to the comparatively short run time (30 min) achievable for multi-residue analysis over other commercially available vancomycin columns (McKenzie et al. 2020). Operation in polar ionic mode using a mobile phase of 2 mM ammonium acetate in methanol containing 0.01% acetic acid facilitated simultaneous enantioseparations (Fig. 1). In total, 12 of 15 drugs achieved the minimum enantiomer resolution ($R_S$) threshold of 1 for quantitative purposes (Evans et al. 2015). The remaining drugs had enantiomer $R_S$ of 0.5–0.8 and the valley drop method was used for integration (Camacho-Muñoz and Kasprzyk-Hordern 2017). The inclusion of $R/S(\pm)$-desmethylcitalopram required a run time of 40 min (Fig. 1). Nevertheless, this remains shorter than previous enantioselective methods for $R/S(\pm)$-desmethylcitalopram which require ≥ 80 min (Evans et al. 2015).

Accelerated solvent extraction was used due to its previous success for extraction of drugs from soil followed by enantioselective analysis (Petrie et al. 2018). However, it was not possible to directly apply this extraction method to sediments. Extraction of 5 g (freeze dried) organic rich sediment resulted in loss of chiral recognition for most drugs in subsequent enantioselective analysis. Therefore, a new

![Fig. 1 Enantioselective liquid chromatography–tandem mass spectrometry chromatograms of studied drugs at 100 ng mL$^{-1}$. Each chromatogram shows the monitored MS/MS transition and enantiomer resolution. Key: $E_1$, enantiomer 1; $E_2$, enantiomer 2 (where order of enantiomer elution is not known). $S(-)$, $S(-)$-enantiomer; $R(\pm)$, $R(\pm)$-enantiomer; $S(\mp)$, $S(\mp)$-enantiomer; $R(-)$, $R(-)$-enantiomer (where order of enantiomer elution is known)](image-url)
Enantiomeric profiling of chiral drugs in sediments

The new methodology was applied to freshwater sediments collected in North-East Scotland (Fig. 3). Sampling focused on a small stream impacted by septic tank discharge (Ramage et al. 2019). The receiving river impacted by both wastewater treatment plant effluent and septic tanks was also sampled. Within the small stream, sediment was collected from a control site with no upstream households. Here, the surrounding land use was arable crop with no biosolids or animal slurry applications within the last two years. No drug enantiomers were detected at this location (Fig. 3).

Samples 1–3 were collected downstream of a suspected septic tank effluent discharge point (without dissipation though a soak away) (Ramage et al. 2019). Both fluoxetine and amphetamine were present. Concentrations of $S(+)$-fluoxetine ranged from 1.6 to 5.0 ng g$^{-1}$ and...
Environmental Chemistry Letters

R(−)-fluoxetine from 1.0 to 3.4 ng g⁻¹ (Fig. 3). Chiral drug composition was described using enantiomeric fraction:

\[
\text{Enantiomeric fraction} = \frac{\text{(+)} - \text{(−)}}{\text{(+)} + \text{(−)}}
\]

Table 1: Performance data of the accelerated solvent extraction-solid phase extraction-enantioselective liquid chromatography–tandem mass spectrometry methodology

| Drug group  | Enantiomer       | Method trueness (% ± SD)a | Signal suppression (%)b | MDL (ng g⁻¹)c | MQL (ng g⁻¹)d |
|-------------|------------------|----------------------------|--------------------------|---------------|---------------|
|             |                  | 10 ng g⁻¹  | 50 ng g⁻¹  | 100 ng g⁻¹ |                |               |
| Beta-blocker| Metoprolol-E1    | 96 ± 12  | 99 ± 4    | 87 ± 3   | 3              | 0.26          | 0.81          |
|             | Metoprolol-E2    | 96 ± 15  | 100 ± 5   | 95 ± 4   | 13             | 0.28          | 0.87          |
|             | Bisoprolol-E1    | 104 ± 11 | 101 ± 5   | 90 ± 2   | 14             | 0.03          | 0.13          |
|             | Bisoprolol-E2    | 106 ± 12 | 97 ± 4    | 99 ± 3   | 21             | 0.03          | 0.13          |
|             | S(−)-propranolol | 101 ± 15 | 102 ± 4   | 95 ± 1   | 17             | 0.10          | 0.32          |
|             | R(+) -propranolol| 94 ± 2   | 100 ± 4   | 102 ± 3  | 18             | 0.10          | 0.34          |
|             | Acebutolol-E1    | 102 ± 8  | 95 ± 5    | 91 ± 4   | 4              | 0.03          | 0.11          |
|             | Acebutolol-E2    | 104 ± 18 | 99 ± 2    | 101 ± 3  | 34             | 0.05          | 0.19          |
|             | S(−)-atenolol    | 107 ± 9  | 102 ± 1   | 95 ± 4   | 19             | 0.91          | 3.05          |
|             | R(+) -atenolol   | 100 ± 7  | 102 ± 1   | 101 ± 3  | 2              | 0.85          | 2.84          |
|             | Sotalol-E1       | 96 ± 5   | 102 ± 3   | 90 ± 2   | 2              | 0.38          | 1.24          |
|             | Sotalol-E2       | 95 ± 9   | 98 ± 4    | 96 ± 6   | 29             | 0.55          | 1.78          |
| Beta-agonist| Salbutamol-E1    | 106 ± 1  | 103 ± 3   | 92 ± 2   | −15            | 0.08          | 0.24          |
|             | Salbutamol-E2    | 102 ± 3  | 98 ± 2    | 101 ± 3  | −28            | 0.08          | 0.24          |
| Stimulant   | S(+) -amphetamine| 104 ± 13 | 98 ± 2    | 88 ± 4   | 17             | 0.07          | 0.26          |
|             | R(−)-amphetamine| 103 ± 1  | 101 ± 2   | 98 ± 3   | 11             | 0.06          | 0.24          |
|             | S(+) -methamphetamine| 104 ± 16 | 100 ± 3   | 93 ± 3   | 26             | 0.05          | 0.15          |
|             | R(−)-methamphetamine| 99 ± 17 | 95 ± 3    | 99 ± 6   | 28             | 0.07          | 0.20          |
| Anti-histamine| S(+) -chlorpheniramine| 103 ± 7 | 86 ± 4    | 95 ± 13  | 21             | 0.19          | 0.64          |
|             | R(−)-chlorpheniramine| 103 ± 12 | 91 ± 6  | 96 ± 9   | 22             | 0.34          | 1.14          |
| Anti-depressant| S(+) -fluoxetine| 102 ± 11 | 98 ± 6    | 93 ± 4   | 27             | 0.42          | 1.33          |
|             | R(−)-fluoxetine  | 99 ± 7   | 94 ± 5    | 99 ± 6   | 20             | 0.31          | 1.00          |
|             | Venlafaxine-E1   | 90 ± 17  | 99 ± 4    | 94 ± 7   | 11             | 0.03          | 0.14          |
|             | Venlafaxine-E2   | 100 ± 20 | 103 ± 3   | 101 ± 5  | 13             | 0.04          | 0.17          |
|             | Desmethylvenlafaxine-E1 | 113 ± 13 | 109 ± 7 | 109 ± 11 | 24              | 0.14          | 0.47          |
|             | Desmethylvenlafaxine-E2 | 112 ± 17 | 121 ± 5   | 115 ± 14 | 22              | 0.12          | 0.43          |
|             | R(−)-citalopram  | 103 ± 16 | 102 ± 7   | 103 ± 11 | 42             | 0.29          | 0.99          |
|             | S(+) -citalopram | 104 ± 11 | 102 ± 10  | 105 ± 8  | 30             | 0.30          | 1.04          |
|             | Desmethylcitalopram-E1 | 120 ± 13 | 112 ± 11 | 105 ± 3  | 32             | 0.28          | 0.94          |
|             | Desmethylcitalopram-E2 | 112 ± 8 | 104 ± 16 | 108 ± 17 | 37             | 0.31          | 1.06          |

SD, standard deviation; MDL, method detection limit; MQL, method quantitation limit

aTrueness(%) = \frac{(\text{Conc}_c - \text{Conc}_s)}{\text{Spike}} \times 100 where \text{Conc}_c is the determined concentration of the spiked sample, \text{Conc}_s is the concentration of the unspiked sample and \text{Spike} is the spiked concentration.

bSignal suppression(%) = 100 - \left( \frac{\text{Slope}_{MM}}{\text{Slope}_{SF}} \times 100 \right) where \text{Slope}_{MM} is the slope of the external calibration prepared in matrix and \text{Slope}_{SF} is the slope of the external calibration prepared in methanol.

cMDL (ng g⁻¹) = \frac{3 \times \text{IDL} \times 100}{\text{Rec} \times \text{CF}}

dMQL (ng g⁻¹) = \frac{5 \times \text{IQL} \times 100}{\text{Rec} \times \text{CF}} where \text{S} is the volume of sample used for extraction divided by the mass of sample extracted (mL g⁻¹). IDL and IQL are the instrument detection and quantitation limits, respectively (ng mL⁻¹), Rec is the absolute recovery (%), not accounting for the deuterated surrogate response and CF is the concentration factor.

R(−)-fluoxetine from 1.0 to 3.4 ng g⁻¹ (Fig. 3). Chiral drug composition was described using enantiomeric fraction:

Enantiomeric fraction = \frac{(+) - (−)}{(+) + (−)}

Here (+) is the concentration of the (+)-enantiomer and (−) is the concentration of the (−)-enantiomer. In each sediment an enrichment of S(+) -fluoxetine resulted in enantiomeric fractions of 0.59–0.61. The enantiomeric composition of

© Springer
fluoxetine in sediments agrees with other environmental matrices such as wastewater effluent (Evans et al. 2015). All amphetamine enantiomers were present at concentrations in the range 2.1–5.4 ng g⁻¹ (Fig. 3). An enrichment of $R$(-)-amphetamine resulted in enantiomeric fractions of 0.39–0.44. This corresponds with previous research whereby amphetamine in this stream water was 470 ng L⁻¹ with an enantiomeric fraction of 0.43 (Ramage et al. 2019). Interestingly, < 1 km downstream (prior to the stream discharge into the receiving river), no drug enantiomers were found. This indicates a localised impact of septic tanks to sediments. However, differences in the composition of sediments could play a role (Al-Khazrajy and Boxall 2016), and requires further investigation for this catchment.

In the sediment sample collected from the receiving river, enantiomers of seven drugs were present. Enantiomer concentrations of the beta-blockers acebutolol, bisoprolol and metoprolol were below quantitation limits (Fig. 3). $S$(-)-propranolol and $R$(-)-propranolol were present at 4.1 ± 1.4 ng g⁻¹ and 3.5 ± 1.0 ng g⁻¹, respectively. This is in agreement with other environmental studies whereby enrichment of $S$(-)-propranolol is typically observed (Fono and Sedlak 2005). Enantiomers of the antidepressants venlafaxine, fluoxetine and citalopram were at low ng g⁻¹ concentrations and enantiomeric fractions of 0.50, 0.60 and 0.40, respectively (Fig. 3). The study showed that the most drugs in freshwater sediments were non-racemic (enantiomeric fraction ≠ 0.50). Therefore, further investigation is needed on the enantiospecific fate and effects of chiral drugs in freshwater sediments.

**Conclusion**

Reported here is the first analytical method for the multi-residue enantioselective profiling of chiral drugs in river sediment. Application of the methodology revealed the enantiomeric composition of several drug in sediment for the first time including fluoxetine, amphetamine, propranolol, venlafaxine and citalopram. Most of the drugs were present in non-racemic form demonstrating further enantiospecific investigations are needed in sediments. Such studies can be facilitated using this new multi-residue methodology.

**Acknowledgements** Support by the Analytical Chemistry Trust Fund is acknowledged.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Al-Khazrajy OSA, Boxall ABA (2016) Impacts of compound properties and sediment characteristics on the sorption behaviour of pharmaceuticals in aquatic systems. J Hazard Mater 317:198–209. https://doi.org/10.1016/j.jhazmat.2016.05.065

Al-Khazrajy OSA, Boxall ABA (2017) Determination of pharmaceuticals in freshwater sediments using ultrasonic-assisted extraction with SPE clean-up and HPLC-DAD or LC-ESI-MS/MS detection. Anal Methods 9(28):4190–4200. https://doi.org/10.1039/c7ay00650k

Bagnis S, Fitzsimons MF, Snape J et al (2018) Processes of distribution of pharmaceuticals in surface freshwaters: implications for risk assessment. Environ Chem Lett 16:1193–1216. https://doi.org/10.1007/s10311-018-0742-7

Camacho-Muñoz D, Kasprzyk-Hordern B (2017) Simultaneous enantiomeric analysis of pharmacologically active compounds in environmental samples by chiral LC–MS/MS with a macrocyclic antibiotic stationary phase. J Mass Spectrom 52(2):94–108. https://doi.org/10.1002/jms.3904

Cizmas L, Sharma VK, Gray CM, McDonald TJ (2015) Pharmaceutical and personal care products in waters: occurrence, toxicity, and risk. Environ Chem Lett 13:361–394. https://doi.org/10.1007/s10311-015-0524-4

De Andrés F, Castañeda G, Rios A (2009) Use of toxicity assays for enantiomeric discrimination of pharmaceutical substances. Chirality 21(8):751–759. https://doi.org/10.1002/chir.20675

Evans SE, Davies P, Lubben A et al (2015) Determination of chiral pharmaceuticals and illicit drugs in wastewater and sludge using microwave assisted extraction, solid-phase extraction and chiral liquid chromatography coupled with tandem mass spectrometry. Anal Chim Acta 882:112–126. https://doi.org/10.1016/j.aca.2015.03.039

Fono LJ, Sedlak DL (2005) Use of the chiral pharmaceutical propranolol to identify sewage discharges into surface waters. Environ Sci Technol 39(23):9244–9252. https://doi.org/10.1021/es047965t

Huang Q, Wang Z, Wang C et al (2013) Chiral profiling of azole antifungals in municipal wastewater and recipient rivers of the Pearl River Delta. China Environ Sci Pollut Res 20(12):8890–8899. https://doi.org/10.1007/s11356-013-1862-z

Kasprzyk-Hordern B (2010) Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev 39(11):4466–4503. https://doi.org/10.1039/c000408c

McKenzie K, Moffat CF, Petrie B (2020) Multi-residue enantioselective determination of emerging drug contaminants in seawater by solid phase extraction and liquid chromatography-tandem mass spectrometry. Anal Methods 12:2881–2892. https://doi.org/10.1039/D0AY00801J

Nieto A, Borrull F, Pocurull E et al (2010) Pressurized liquid extraction: A useful technique to extract pharmaceuticals and personal care products from sewage sludge. Trends Anal Chem 29(7):752–764. https://doi.org/10.1016/j.trac.2010.03.014

Petrie B, Mrazova J, Kasprzyk-Hordern B et al (2018) Multi-residue analysis of chiral and achiral trace organic contaminants in soil by accelerated solvent extraction and enantioselective liquid chromatography tandem–mass spectrometry. J Chromatogr A 1572:62–71

Ramage S, Camacho-Muñoz D, Petrie B (2019) Enantioselective LC-MS/MS for anthropogenic markers of septic tank discharge. Chemosphere 219:191–201. https://doi.org/10.1016/j.chemosphere.2018.12.007

Ribeiro AR, Castro PML, Tiritan ME (2012) Chiral pharmaceuticals in the environment. Environ Chem Lett 10:239–253. https://doi.org/10.1007/s10311-011-0352-0

Ribeiro AR, Afonso CM, Castro PML et al (2013) Enantioselective HPLC analysis and biodegradation of atenolol, metoprolol and fluoxetine. Environ Chem Lett 11:83–90. https://doi.org/10.1007/s10311-012-0383-1

Schaidler LA, Rodgers KM, Rudel RA (2017) Review of organic wastewater compound concentrations and removal in onsite wastewater treatment systems. Environ Sci Technol 51(13):7304–7317. https://doi.org/10.1021/acs.est.6b04778

Silva BFD, Jelic A, López-Serna R et al (2011) Occurrence and distribution of pharmaceuticals in surface water, suspended solids and sediments of the Ebro river basin. Spain Chemosphere 85(8):1331–1339. https://doi.org/10.1016/j.chemosphere.2011.07.051

Stanley JK, Ramirez AJ, Chambliss CK et al (2007) Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. Chemosphere 69(1):9–16. https://doi.org/10.1016/j.chemosphere.2007.04.080

Vázquez-Roig P, Segarra R, Blasco C et al (2010) Determination of pharmaceuticals in soils and sediments by pressurized liquid extraction and liquid chromatography tandem mass spectrometry. J Chromatogr A 1217(16):2471–2483. https://doi.org/10.1016/j.chroma.2009.11.033

Wilkinson J, Hooda PS, Barker J et al (2017) Occurrence, fate and transformation of emerging contaminants in water: An overarching review of the field. Environ Pollut 231:954–970. https://doi.org/10.1016/j.envpol.2017.08.032

Xue M, Qin Y, Gu X et al (2018) Determination of fluoxetine enantiomers and 7-hydroxyfluoxetine in water and sediment by chiral HPLC coupled with hybrid quadrupole-time-of-flight mass spectrometer. Sci Rep 8(1):7582. https://doi.org/10.1038/s41598-018-25889-5

Yuan X, Li X, Guo P et al (2018) Simultaneous enantiomeric analysis of chiral non-steroidal anti-inflammatory drugs in water, river sediment, and sludge using chiral liquid chromatography-tandem mass spectrometry. Anal Methods 10(36):4404–4413. https://doi.org/10.1039/c8ay01417e

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary material

Multi-residue enantioselective analysis of chiral drugs in freshwater sediments

Abbey Eaglesham*, Arron Scott*, Bruce Petrie*

*a School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, AB10 7GJ, UK
*Corresponding author email: b.r.petrie@rgu.ac.uk Tel. +44 (0)1224 262824

The electronic supplementary material contains three tables detailing the physicochemical properties of studied drugs, their multiple reaction monitoring transitions and instrument performance information.
| Enantiomer          | Molecular formula | Molecular weight (g/mol) | Water solubility (mg/L) | Log \( K_{ow} \) | pKa (most acidic) | pKa (most basic) |
|---------------------|-------------------|--------------------------|-------------------------|------------------|------------------|-----------------|
| R/S(+)-metoprolol   | C₁₅H₂₅NO₃        | 267.37                   | 4.77x10³                 | 1.69             | 13.89            | 9.43            |
| R/S(+)-bisoprolol   | C₁₈H₃₁NO₄        | 325.44                   | 2.24 x10³                | 1.84             | 13.86            | 9.42            |
| R/S(+)-propranolol  | C₁₆H₂₁NO₂        | 259.35                   | 228                     | 2.60             | 13.84            | 9.50            |
| R/S(+)-acebutolol   | C₁₈H₂₆NO₄        | 336.43                   | 259                     | 1.71             | 13.91            | 9.57            |
| R/S(+)-atenolol     | C₁₄H₂₂N₂O₃      | 266.34                   | 685                     | -0.03            | 13.88            | 9.43            |
| R/S(+)-sotalol      | C₁₂H₂₀N₂O₃S     | 272.36                   | 5.51x10¹                 | 0.24             | 10.07            | 9.43            |
| R/S(+)-salbutamol   | C₁₀H₂₁NO₃       | 239.31                   | 1.43x10⁴                 | 0.64             | 10.12            | 9.40            |
| R/S(+)-amphetamine | C₅H₁₃N          | 135.21                   | 2.80x10⁴                 | 1.76             | -                | 9.94            |
| R/S(+)-methamphetamine | C₁₀H₁₃N     | 149.24                   | 1.33x10⁴                 | 2.22             | -                | 10.38           |
| R/S(+)-chlorpheniramine | C₁₀H₉ClN₂   | 274.79                   | 5.50x10³                 | 3.38             | -                | 9.47            |
| R/S(+)-fluoxetine   | C₁₇H₁₈F₂NO      | 309.33                   | 60.3                    | 4.65             | -                | 10.05           |
| R/S(+)-venlafaxine  | C₁₇H₂₇NO₂       | 277.41                   | 267                     | 3.28             | 14.84            | 9.26            |
| R/S(+)-desmethylvenlafaxine | C₁₆H₂₃NO₂ | 263.38                   | -                       | -                | 10.04            | 9.33            |
| R/S(+)-citalopram   | C₂₀H₂₁FN₂O      | 324.40                   | 31.1                    | 3.74             | -                | 9.57            |
| R/S(+)-desmethylcitalopram | C₁₀H₁₀FN₂O | 310.40                   | 5.2                     | 3.38             | -                | 10.54           |
Table S2. Multiple reaction monitoring transitions of all drugs and deuterated surrogates

| Drugs | Rₜ (minutes) | Precursor (m/z) | Fragmentor (V) | Product 1 (m/z) | CE (eV) | Product 2 (m/z) | CE (eV) |
|-------|--------------|----------------|----------------|----------------|---------|----------------|---------|
| R/S(±)-metoprolol | 10.0, 10.9 | 268.1 | 110 | 116.0 | 12 | 191.1 | 10 |
| R/S(±)-bisoprolol | 9.5, 10.1 | 326.2 | 120 | 116.0 | 10 | 74.1 | 30 |
| R/S(±)-propranolol | 12.4, 13.9 | 259.9 | 110 | 115.9 | 10 | 182.9 | 10 |
| R/S(±)-acebutolol | 14.0, 15.6 | 337.2 | 90 | 116.1 | 20 | 319.3 | 10 |
| R/S(±)-atenolol | 18.1, 19.7 | 266.9 | 100 | 145.0 | 30 | 189.9 | 20 |
| R/S(±)-sotalol | 13.0, 15.3 | 273.1 | 90 | 133.0 | 10 | 255.1 | 30 |
| R/S(±)-salbutamol | 8.1, 9.2 | 239.9 | 90 | 147.9 | 10 | 165.9 | 10 |
| R/S(±)-amphetafine | 12.3, 14.2 | 135.8 | 70 | 90.9 | 20 | 65.0 | 40 |
| R/S(±)-methamphetamine | 16.0, 17.9 | 150.0 | 90 | 91.0 | 20 | 65.0 | 40 |
| R/S(±)-chlorpheniramine | 18.8, 20.7 | 274.9 | 90 | 229.9 | 10 | 166.8 | 40 |
| R/S(±)-fluoxetine | 15.8, 19.8 | 309.8 | 90 | 44.0 | 10 | 147.7 | 2 |
| R/S(±)-venlafaxine | 11.8, 13.3 | 278.1 | 90 | 58.1 | 20 | 121.1 | 30 |
| R/S(±)-desmethylvenlafaxine | 10.8, 12.6 | 264.1 | 90 | 246.1 | 10 | 106.9 | 30 |
| R/S(±)-citalopram | 21.0, 23.6 | 325.1 | 110 | 108.9 | 30 | 261.8 | 20 |
| R/S(±)-desmethylcitalopram | 21.5, 33.6 | 311.0 | 110 | 108.9 | 20 | 262.0 | 10 |
| R/S(±)-metoprolol-d₁₇ | 10.1, 10.9 | 275.2 | 110 | 123.0 | 15 | - | - |
| R/S(±)-bisoprolol-d₃ | 9.6, 10.2 | 331.2 | 120 | 121.0 | 10 | - | - |
| R/S(±)-propranolol-d₁₇ | 12.4, 14.4 | 267.0 | 110 | 115.9 | 20 | - | - |
| R/S(±)-acebutolol-d₃ | 14.1, 15.8 | 342.2 | 90 | 121.0 | 20 | - | - |
| R/S(±)-atenolol-d₁₇ | 18.2, 19.8 | 274.1 | 110 | 145.0 | 30 | - | - |
| R/S(±)-sotalol-d₆ | 13.0, 15.3 | 279.1 | 90 | 133.9 | 30 | - | - |
| R/S(±)-salbutamol-d₁ | 8.2, 9.3 | 243.0 | 90 | 150.9 | 10 | - | - |
| R/S(±)-amphetamine-d₁₁ | 12.4, 14.4 | 147.0 | 70 | 98.0 | 20 | - | - |
| R/S(±)-methamphetamine-d₁₁ | 16.0, 18.0 | 161.1 | 90 | 97.0 | 20 | - | - |
| R/S(±)-chlorpheniramine-d₁₀ | 20.2, 22.2 | 281.0 | 100 | 229.9 | 10 | - | - |
| R/S(±)-fluoxetine-d₁₀ | 15.8, 19.9 | 316.0 | 90 | 44.1 | 10 | - | - |
| R/S(±)-venlafaxine-d₁₀ | 11.8, 13.3 | 284.1 | 90 | 58.1 | 20 | - | - |
| R/S(±)-citalopram-d₁₀ | 22.3, 25.0 | 331.0 | 130 | 109.0 | 30 | - | - |

Key: CE, collision energy
| Enantiomer                  | Linear range (ng mL\(^{-1}\)) | \(r^2\) | Intraday precision (%) | Interday precision (%) | IDL (ng mL\(^{-1}\)) | IQL (ng mL\(^{-1}\)) |
|-----------------------------|---------------------------------|--------|------------------------|------------------------|----------------------|------------------------|
| Metoprolol-E1               | 0-250                           | 0.995  | 6.3                    | 0.6                    | 2.1                  | 2.0                    | 2.0                   | 0.6                  | 1.8                  | 0.8                  | 2.5                  |
| Metoprolol-E2               | 0-250                           | 0.997  | 4.0                    | 0.7                    | 1.0                  | 3.5                    | 1.4                  | 0.7                  | 0.8                  | 2.5                  |
| Bisoprolol-E1               | 0-250                           | 0.999  | 2.8                    | 0.5                    | 0.8                  | 1.7                    | 0.8                  | 0.5                  | 0.1                  | 0.4                  |
| Bisoprolol-E2               | 0-250                           | 1.000  | 2.5                    | 3.2                    | 2.2                  | 1.3                    | 2.1                  | 2.4                  | 0.1                  | 0.4                  |
| S(-)-propranolol            | 0-250                           | 1.000  | 0.9                    | 2.2                    | 2.0                  | 5.3                    | 2.6                  | 1.1                  | 0.3                  | 1.0                  |
| R(+)-propranolol            | 0-250                           | 1.000  | 4.4                    | 2.2                    | 1.7                  | 1.9                    | 6.7                  | 1.1                  | 0.3                  | 1.0                  |
| Acebutolol-E1               | 0-250                           | 1.000  | 2.6                    | 0.6                    | 0.7                  | 0.2                    | 1.4                  | 1.0                  | 0.1                  | 0.4                  |
| Acebutolol-E2               | 0-250                           | 0.999  | 5.8                    | 2.8                    | 2.4                  | 2.1                    | 0.2                  | 4.5                  | 0.1                  | 0.4                  |
| S(-)-atenolol               | 0-250                           | 0.999  | 4.0                    | 1.7                    | 1.5                  | 9.0                    | 0.8                  | 0.8                  | 1.5                  | 5.0                  |
| R(+)-atenolol               | 0-250                           | 1.000  | 3.9                    | 2.2                    | 2.0                  | 1.6                    | 2.9                  | 0.5                  | 1.5                  | 5.0                  |
| Sotalol-E1                  | 0-250                           | 1.000  | 10.5                   | 0.5                    | 2.2                  | 4.1                    | 0.7                  | 2.1                  | 1.3                  | 4.2                  |
| Sotalol-E2                  | 0-250                           | 0.999  | 4.0                    | 0.6                    | 1.1                  | 3.6                    | 0.8                  | 0.6                  | 1.3                  | 4.2                  |
| Salbutamol-E1               | 0-250                           | 1.000  | 3.8                    | 2.0                    | 4.0                  | 6.4                    | 1.5                  | 1.8                  | 0.1                  | 0.3                  |
| Salbutamol-E2               | 0-250                           | 0.999  | 1.1                    | 3.3                    | 1.6                  | 1.3                    | 1.3                  | 0.7                  | 0.1                  | 0.3                  |
| S(+)-amphetamine           | 0-250                           | 0.999  | 2.8                    | 2.4                    | 1.8                  | 1.0                    | 1.3                  | 1.7                  | 0.1                  | 0.4                  |
| R(-)-amphetamine           | 0-250                           | 0.999  | 3.4                    | 2.7                    | 1.4                  | 0.9                    | 0.6                  | 0.2                  | 0.1                  | 0.4                  |
| S(+)-methamphetamine       | 0-250                           | 1.000  | 1.2                    | 0.4                    | 1.7                  | 1.8                    | 1.1                  | 1.4                  | 0.1                  | 0.2                  |
| R(-)-methamphetamine       | 0-250                           | 1.000  | 1.9                    | 0.9                    | 0.4                  | 1.7                    | 0.3                  | 0.2                  | 0.1                  | 0.2                  |
| S(+)-chlorpheniramine       | 0-250                           | 1.000  | 2.1                    | 2.4                    | 0.2                  | 3.1                    | 2.1                  | 2.5                  | 0.3                  | 1.0                  |
| R(-)-chlorpheniramine       | 0-250                           | 1.000  | 3.8                    | 3.6                    | 0.8                  | 2.7                    | 3.1                  | 4.9                  | 0.3                  | 1.0                  |
| S(+)-fluoxetine             | 0-250                           | 0.999  | 3.7                    | 1.4                    | 2.0                  | 1.7                    | 0.6                  | 0.5                  | 0.5                  | 1.6                  |
| R(-)-fluoxetine             | 0-250                           | 1.000  | 4.9                    | 1.5                    | 2.0                  | 3.0                    | 1.1                  | 0.7                  | 0.5                  | 1.6                  |
| Venlafaxine-E1              | 0-250                           | 1.000  | 8.2                    | 2.3                    | 2.2                  | 11.4                   | 10.4                 | 2.6                  | 0.1                  | 0.4                  |
| Venlafaxine-E2              | 0-250                           | 1.000  | 2.0                    | 1.4                    | 0.3                  | 1.1                    | 1.5                  | 1.4                  | 0.1                  | 0.4                  |
| Desmethylvenlafaxine-E1     | 0-250                           | 0.998  | 1.5                    | 5.1                    | 0.5                  | 10.1                   | 4.6                  | 1.8                  | 0.4                  | 1.4                  |
| Desmethylvenlafaxine-E2     | 0-250                           | 0.996  | 1.4                    | 2.2                    | 1.5                  | 3.2                    | 2.9                  | 0.5                  | 0.4                  | 1.4                  |
| R(-)-citalopram             | 0-250                           | 0.999  | 5.3                    | 4.0                    | 1.5                  | 1.9                    | 2.4                  | 2.1                  | 0.5                  | 1.7                  |
| S(+)-citalopram             | 0-250                           | 0.998  | 4.2                    | 1.9                    | 3.9                  | 0.5                    | 1.9                  | 2.9                  | 0.5                  | 1.7                  |
| Desmethylcitalopram-E1      | 0-250                           | 0.999  | 3.8                    | 2.1                    | 3.7                  | 1.1                    | 2.1                  | 3.2                  | 0.5                  | 1.7                  |
| Desmethylcitalopram-E2      | 0-250                           | 0.997  | 4.1                    | 2.3                    | 3.5                  | 1.3                    | 2.1                  | 2.9                  | 0.5                  | 1.7                  |

Key: IDL, instrument detection limit; IQL, instrument quantitation limit;
